Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
USD bond abnormal movement | Shandong Shipping SDSHIP 5 08/18/25 price dropped by 1.478%, reported at 100.000
21/05/2025
On May 21st, the SDSHIP 5 08/18/25 issued by Shandong Shipping is currently priced at 100.000, down -1.478% with a yield of 4.935%.
Latest
4 m ago
Price of Vanke Corporation VNKRLE 3.975 11/09/27 rose by 1.173% to 84.000.
4 m ago
Movement in US dollar bonds | Sunac China's SUNAC 0 09/30/28 price increased by 2.128% to reach 12.000.
5 m ago
Roche announced that the Phase III TALENTACE study has reached its primary endpoint. The study evaluated the efficacy and safety of atezolizumab, bevacizumab, and on-demand transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The study showed a statistically and clinically significant improvement in TACE-induced progression-free survival (TACE-PFS, defined as the time from randomization to the investigator-assessed TACE-unrecoverable progression or TACE failure/resistance, or death for any reason) at the time of the interim analysis, with overall survival (OS) data still immature. Furthermore, a clinically meaningful improvement in PFS assessed by RECIST v1.1 was also observed.
5 m ago
Roche: The clinical study of liver cancer stage III TALENTACE has achieved the main research endpoint.
5 m ago
Former chairman Zhou Yiming of Sichuan Province International Supply Chain Management Co., Ltd. is under investigation.
See all latest